A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis.

ABSTRACT:

Background

Interleukin 12 (IL-12), a cytokine that promotes generation of helper T cells subtype 1, is increased in multiple sclerosis. Albuterol sulfate, a β2-adrenergic agonist, reduces IL-12 expression, so we tested the effect of albuterol as an add-on treatment to glatiramer acetate therapy.

Objectives

To investigate the clinical and immunologic effects of albuterol treatment as an add-on therapy in patients starting glatiramer acetate treatment.

Design

Single-center double-masked clinical trial.

Setting

Academic research. Patients Subjects with relapsing-remitting multiple sclerosis.

Main outcome measures

In this single-center double-masked clinical trial, subjects with relapsing-remitting multiple sclerosis were randomized to receive a subcutaneous

SUBMITTER: Khoury SJ 

PROVIDER: S-EPMC2954052 | biostudies-literature | 2010 Sep

REPOSITORIES: biostudies-literature